ANDA 204494, held by Pai Holdings Pharm. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 204494 (Lidocaine Hydrochloride), held by Pai Holdings Pharm, was first approved by FDA on Mar 12, 2014, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Topical Solution USP, 4% is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
| Aug 18, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 12, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters